Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Abstract Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation. The introduction of biologics has improved the treatment options for SJIA. Canakinumab selectively inhibits...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-10-01
Colecção:	Pediatric Rheumatology Online Journal
Assuntos:	Systemic juvenile idiopathic arthritis Canakinumab CARRA registry Safety
Acesso em linha:	https://doi.org/10.1186/s12969-025-01144-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!